Trial Profile
Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon [dimebolin] in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2015
Price :
$35
*
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Medivation
- 10 Feb 2010 Endpoint methodology added (where possible).
- 09 Sep 2008 Primary efficacy results from the open-label extension phase presented at ADRD in July 2008
- 26 Jul 2008 Primary endpoint results presenetd at ADRD in July 2008